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ABSTRACT 
 
Role of Inflammation and Endothelial Dysfunction  
of Coronary Arterioles in Type 2 Diabetes. (August 2008) 
Ji Yeon Yang, B.S., Dongduk Women’s University 
Co-Chairs of Advisory Committee: Dr. Cuihua Zhang 
                                                         Dr. Glen A. Laine  
 
 
We hypothesized that the interaction between tumor necrosis factor alpha 
(TNFα)/nuclear factor-kappaB (NFκB) via activation of IKKβ may amplify one another 
resulting in the evolution of vascular disease and insulin resistance associated with 
diabetes. The interaction between TNFα and monocyte chemoattractant protein-1 (MCP-
1) may contribute to the evolution of vascular inflammation and endothelial dysfunction 
in coronary arterioles in type 2 diabetes. To test this hypothesis, endothelium-dependent 
(ACh) and –independent (SNP) vasodilation of isolated, pressurized coronary arterioles 
(40-100 µm) from mLeprdb (heterozygote, normal), Leprdb (homozygote, diabetic) and 
Leprdb mice null for TNFα (dbTNF-/dbTNF-) were examined. Although dilation of vessels 
to SNP was not different between Leprdb and mLeprdb mice, dilation to ACh was reduced 
in Leprdb mice. The NFκB antagonist, MG-132, IKKβ inhibitor, sodium salicylate 
(NaSal), or Anti-MCP-1 partially restored endothelium-dependent coronary arteriolar 
dilation in Leprdb mice. Protein expression of IKKα and IKKβ were higher in Leprdb than 
in mLeprdb mice. The expression of IKKβ, but not the expression of IKKα was increased 
in dbTNF-/dbTNF- mice. Leprdb mice showed increased insulin resistance, but NaSal 
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improved insulin sensitivity. Protein expression of TNFα, NFκB, phosphorylation of 
IKKβ and JNK were greater in Leprdb mice, but NaSal attenuated protein expression of 
them in Leprdb mice. The ratio of phosphorylated IRS-1 at Ser307 (pIRS-1)/IRS-1 
protein expression was elevated in Leprdb mice; both NaSal and JNK inhibitor SP600125 
reduced pIRS-1/IRS-1 in Leprdb mice. MG-132 or neutralization of TNFα reduced 
superoxide production in Leprdb mice. Anti-MCP-1 attenuated superoxide production 
and protein expression of nitrotyrosine (N-Tyr), which is an indicator of peroxynitrite 
production, in isolated coronary arterioles of Leprdb mice. Immunostaining results 
showed that expression of MCP-1 and vascular cellular adhesion molecule-1 (VCAM) is 
co-localized with endothelial cells and macrophages. Anti-TNFα or anti-MCP-1 
markedly reduced macrophage infiltration and the number of MCP-1 positive cells. 
Neutralization of TNFα or anti-MCP-1 reduced the expression of adhesion molecules. In 
conclusion, our results indicate that the interaction between NFκB and TNFα signaling 
induces activation of IKKβ. In addition, TNFα and TNFα-related signaling, including 
the expression of MCP-1 and adhesion molecules, further exacerbates oxidative stress 
leading to endothelial dysfunction in type 2 diabetes.  
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CHAPTER I 
INTRODUCTION 
 
A. Feed-forward Signaling of TNFα and NFκB via IKKβ Pathway Induces Insulin  
     Resistance and Coronary Arteriolar Dysfunction in Type 2 Diabetic Mice 
 
 The prevalence of obesity and diabetes has led to a significant increase in the 
complications associated with cardiovascular disease. Many of these complications can 
be linked to a dysregulation of the body's immune system.1,2 Tumor necrosis factor alpha 
(TNFα) is a pro-inflammatory cytokine that has been implicated in cardiovascular 
diseases.3,4 We previously found that increases in TNFα expression induces activation of 
NAD(P)H oxidase and the production of reactive oxidative species (ROS), leading to 
endothelial dysfunction in type 2 diabetes.5 Importantly, TNFα activates the 
transcription nuclear factor-kappaB (NFκB), which regulates the expression of genes 
involved in inflammation, oxidative stress and endothelial dysfunction.5 TNFα also 
initiates the signaling cascades via the inhibitor of NFκB (IκB) kinase (IKK) complex, 
which contains IKKα and IKKβ. The inhibitory protein IκBα is phosphorylated, 
ubiquitinated and degraded by proteasomes, releasing NFκB to translocate into the  
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nucleus. Under normal physiological conditions, the inflammatory response is 
terminated by binding NFκB with the inhibitory protein IκB.6,7 Investigation of TNFα-
mediated NFκB pathway is needed to identify specific pro-inflammatory agents in type 
2 diabetes.  
Salicylates, including aspirin and sodium salicylate (NaSal) are common 
nonsteroidal anti-inflammatory drugs (NSAIDs), which have anti-platelet and anti-
inflammatory effects. Aspirin inhibits prostaglandin production, but NaSal has a 
prostaglandin-independent effect. NaSal inhibits the activity of IKKβ, which is required 
for the activation of NFκB. IKKβ, the molecular target of NaSal, is associated with the 
rise of insulin resistance.8,9 Recent work suggests that specific antagonism of the NFκB 
inflammatory pathway through the inhibition of IKKβ reduces acute myocardial damage 
following ischemia-reperfusion injury10 and insulin action plays a critical role in 
reducing myocardial infarct size by increasing cardiac myocyte metabolism.11-13 We 
previously found that TNFα-activated Jun N-terminal kinase (JNK), which mediates 
O2˙¯  production and impairs endothelium-dependent vasodilation in coronary 
arterioles.14 NaSal prevents TNFα-induced JNK activation from blocking insulin 
signaling via a serine phosphorylation.15 Therefore, we evaluated 1) whether reciprocal 
interactions between TNFα and NFκB via activation of IKKβ accentuate the evolution 
of vascular disease in type 2 diabetes; and 2) whether NaSal restores endothelial 
dysfunction and insulin resistance by inhibiting IKKβ/NFκB activity thereby preventing 
JNK activation in coronary arterioles from type 2 diabetes (Leprdb), type 2 diabetic mice 
null for TNFα (dbTNF-/dbTNF-) and lean control (mLeprdb) mice. 
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B. Role of MCP-1 in TNFα-induced Endothelial Dysfunction in Type 2 Diabetic Mice 
Diabetes is accompanied by a maturing inflammatory response that consists of 
increased TNFα and monocyte chemoattractant protein-1 (MCP-1) expression in 
adipocytes and the lumen of vessels.16 At the tissue level, diabetic inflammation 
enhances expression of adhesion molecules, which facilitates macrophage 
infiltration.17~19 The progression of vascular disease in type 2 diabetes is caused by the 
complex interaction of many factors. We previously found that increases in TNFα 
expression induces activation of NAD(P)H oxidase and production of reactive oxidative 
species (ROS), leading to endothelial dysfunction in type 2 diabetes.5 Additionally, 
TNFα is reported to enhance MCP-1 expression;20 thus the interaction between these 
two systems may contribute significantly to the evolution of vascular disease in diabetes. 
MCP-1 is a major component of adipose tissue that contributes to abnormal lipid 
metabolism21 and is expressed by a variety of activated cells (e.g., endothelial cells, 
monocytes, and smooth muscle cells). MCP-1 has been thought to be essential in 
defending the host against foreign organisms and is an important mediator in chronic 
inflammation.22 Many studies suggest that MCP-1 plays a detrimental role in the 
development of vascular disease through recruitment of monocytes that accumulate 
in/on vascular endothelium and may augment vascular disease at the inflammatory 
site.23-25 Monocytes that migrate from the peripheral vasculature into the myocardium 
undergo maturation to macrophages, which then release proteolytic enzymes and 
damage the myocardium.26 The action of MCP-1 on the stages of monocyte recruitment 
(rolling and/or adhesion) is associated with the activation of specific cell surface proteins. 
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In this regard, adhesion molecules (e.g.,vascular cell adhesion molecule-1 [VCAM], 
intracellular adhesion molecule-1 [ICAM], and E-selectin as well as MCP-1) are 
responsible for myocardial injury and cardiac contractile dysfunction.27  
Thus, the goal of this study was to document the cellular and molecular 
mechanisms involved in MCP-1 in the coronary microcirculation in TNFα-induced 
endothelial dysfunction in type 2 diabetes. We examined the role of MCP-1 in type 2 
diabetes, and tested whether the interaction of TNFα and MCP-1 amplifies the signaling 
of adhesion molecules and macrophage infiltration. Endothelial function and the 
production of ROS were determined in isolated coronary arterioles (40-100 µm) from 
genetically modified mice with type 2 diabetes (Leprdb) with and without treatment with 
MCP-1 neutralizing antibody. We also tested the co-localization of MCP-1, CD68 and 
adhesion molecules in type 2 diabetes using immunohistochemical analysis. 
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CHAPTER II 
METHODS 
 
A. Animal Treatment 
1. Animal Model 
The procedures followed were in accordance with approved guidelines set by the 
Laboratory Animal Care and Use Committee at Texas A&M University. Heterozygote 
controls (C57BLKS/J, mLeprdb), homozygote type 2 diabetes (C57BLKS/J, Leprdb) and 
Leprdb null for TNFα (dbTNF-/dbTNF-) mice were purchased from Jackson Laboratory and 
maintained on a normal rodent chow diet. Our studies utilized 12-16 week-old, 20-30 g 
mLeprdb, 40-60 g Leprdb and dbTNF-/dbTNF- mice of either sex. The cross (dbTNF-/dbTNF-) 
of Leprdb with TNFKO is heterozygous for Leprdb and homozygous for TNF KO 
(TNF−/−).The dbTNF-/dbTNF- mice show the phenotypes of hyperglycemia and obesity that 
is consistent with diabetes and the penetrance of the leptin receptor mutation. The obese 
mice from the second round of breeding of Leprdb and TNF−/− mice were used in 
experimentation.  
2. Neutralization and Treatment 
The neutralizing antibody to TNFα28 is 2E2 monoclonal antibody (2E2 MAb. 
94021402, NCI Biological Resources Branch). At 12-16 weeks of age, all mice received 
anti-TNF (2E2 MAb. 0.625 mg/ml/kg/day, 3 days, i.p.); dosage was based on our 
estimates of TNFα expression, which was estimated to be in the low ng or pg range.  
This amount was able to neutralize 10-100 fold more than the estimated levels of TNFα.  
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MG132 tripeptide (Z-Leu-Leu-Leu- aldehyde, Sigma, dissolved in dimethyl 
sulfoxide [DMSO]) is a peptide aldehyde proteasome inhibitor. Ultimately preventing 
IκBα degradation by the proteasome restricts NFκB activity in vitro.7 Leprdb mice were 
injected (10 mg/kg/day for 3 days, i.p.).29 The contribution of NAD(P)H oxidase in 
generating O2˙¯  was assessed by treating mice with the NAD(P)H oxidase inhibitor 
apocynin (100 mg/kg/day, i.p. for 3 days). We administered NaSal (Calbiochem; 6 
mg/ml in drinking water for 7-10 days, pH 7) to Leprdb and mLeprdb mice to determine 
whether blocking IKKβ affects their blood glucose level. To determine whether 
blockage of JNK affects insulin receptor substrate-1 (IRS-1) activity, we also 
administered the JNK inhibitor, SP600125 (CalBiochem, 10 mg/kg/day in 0.05 ml 
DMSO, i.p. for 7 days) to Leprdb mice.30 Mice were treated with the neutralizing 
antibody to MCP-1 (anti-MCP-1; 200 mg/kg/day, i.p. for 3 days, MURINE; Biovision) 
to block MCP-1 signaling. 
 
B. Measurement of Blood Parameters 
Blood was obtained from the vena cava after anesthesia with sodium 
pentobarbital (50 mg/kg; i.p.) and exposure of the vein. Whole blood samples were spun 
at 3,000 rpm for 10 minutes, and serum was stored at -80°C until analysis.  
1. Measurement of Glucose 
We used a OneTouch Ultramini glucometer (LifeScan) for measuring blood 
glucose in mLeprdb, Leprdb and Leprdb mice treated with NaSal at the same time (8:00-
10:00AM) throughout the protocol.  
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2. Serum Cholesterol Level 
Serum cholesterol level was measured with the Cholesterol/Cholesteryl Ester 
Quantitation Kit (Biovision) using spectrophotometry (Multiskan MCC, Fisher 
Scientific). A large portion of cholesterol in blood is in the form of cholesteryl esters. 
Cholesterol esterase hydrolized cholesteryl ester into cholesterol. Cholesterol is then 
oxidized by cholesterol oxidase to yield H2O2. The produced H2O2 interacts with a 
sensitive cholesterol probe. 
3. Serum Insulin Level 
Insulin was measured with the use of a commercial kit, insulin (Mouse) 
Ultrasensitive EIA (ALPCO Diagnostics). Insulin concentration was measured by 
spectrophotometry (Multiskan MCC, Fisher Scientific).  
4. HOMA-IR 
Insulin resistance was determined by utilizing the homeostasis model assessment; 
HOMA-IR using the following formula: 
HOMA-IR= ((non-fasting glucose [mmol/L]) × (non-fasting insulin [mU/L]))/22.5. 
 
C. Functional Study 
1. Preparation of Coronary Microvessels 
The techniques for identification and isolation of coronary microvessels were described 
in detail previously.31,32 Coronary arterial microvessels (<100 µm) were carefully 
dissected out for in vitro study. After isolation, the microvessel was cannulated with two 
glass micropipettes filled with filtered albumin-PSS, and the outside of the microvessel 
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was securely tied to the pipettes with 11-O ophthalmic suture. The preparation was 
transferred to the stage of an inverted microscope coupled to a CCD camera and video 
micrometer (Figure 1). To determine whether NFκB, IKKβ, or MCP-1 was playing a 
role in endothelial injury in type 2 diabetes, the endothelium-dependent vasodilator 
acetylcholine (ACh, 0.1 nmol/L to 10 µmol/L), the endothelial independent vasodilator 
sodium nitroprusside (SNP, 0.1 nmol/L to 10 µmol/L)-induced, and flow-induced 
vasodilation (NO-mediated, endothelial dependent but agonist independent; 4 to 60 cm 
H2O) were assessed in coronary arterioles in mLeprdb, Leprdb, and Leprdb mice treated 
with MG132, NaSal, or anti-MCP-1. Flow was established by the production of a 
pressure drop across the vessel, and linearly related to the pressure drop (∆P).   
 
 
Figure 1. Isolated vessel set-up for coronary arteries.  
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2. Data Analysis 
 At the end of each experiment, the vessel was relaxed with 100 µmol/L SNP to 
obtain its maximal diameter at 60 cm H2O intraluminal pressure.32 All diameter changes 
to pharmacological agonists were normalized to the control diameter and expressed as a 
percentage of control diameter. Functional data are presented as mean±SEM, except as 
specifically stated (e.g. as mean±SD for molecular study). Statistical comparisons of 
vasomotor responses under various treatments were performed with two-way ANOVA 
and intergroup differences were tested with Bonferonni Inequality. Significance was 
accepted at P<0.05.  
3. Insulin Tolerance Test 
The tail was nicked with a fresh razor blade by horizontal cut of the tip and the 
OneTouch Ultramini glucometer was used to measure baseline blood glucose. A total of 
0.75 units per kg body weight of diluted insulin from porcine pancreas (Sigma) was 
injected into the intraperitoneal cavity. Blood samples were taken for glucose 
determinations 0, 30, 60, and 120 minutes later. Blood was sampled from the tail of each 
mouse by gently massaging a small drop of blood onto the glucometer strip.  
 
D. Molecular Study 
1. Electron Paramagnetic Resonance (EPR) Spectroscopy 
Homogenates of (4-6 isolated coronary arterioles) were prepared in a 50 mmol/L 
phosphate buffer containing 0.01 mmol/L EDTA. The homogenate was then subjected to 
low-speed centrifugation (1000 g) for 10 minutes to remove unbroken cells and tissue 
debris. The supernatants containing 2 mmol/L CPH (1-hydrox-3 carboxypyrrolidine) 
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were incubated for 30 minutes at 37 °C and frozen quickly in liquid nitrogen. EPR 
spectroscopy was performed at room temperature using a Bruker EMX spectrometer and 
1 mm diameter capillaries. Superoxide quantitation from the EPR spectra was 
determined by double integration of the peaks, with reference to a standard curve from 
horseradish peroxidase generation of the anion from standard solutions of hydrogen 
peroxide, using p-acetamidophenol as the co-substrate,33,31 then normalized by protein 
concentration.  
2. Immunofluorescence 
Mouse heart was perfused with PBS and then perfused again with 4 % 
paraformaldehyde. Isolated heart tissue was fixed in 4 % paraformaldehyde diluted in 
PBS 0.1 M (overnight at 4 °C). Fixed heart tissue was perfused in 20 % sucrose diluted 
in PBS 0.1 M (overnight at 4 °C). Once the heart was completely perfused, the tissue 
was embedded in OCT and snap-frozen at –60 °C and stored at –80 °C. Frozen tissues 
were sectioned at 5 µm thick, using cryostat (Leica) and slides allowed to dry at room 
temperature; then the tissues were incubated in 0.3 % Triton-100 for 30 minutes and 
washed in PBS 3 times. 5 % goat serum was used for 30 minutes to block nonspecific 
binding. Anti-rat primary MCP-1, VCAM-1 antibodies (Abcam) and anti-rabbit primary 
α-actin, von Wilibrand factor (VWF), anti-mouse primary CD68 (Abcam) as 
monocyte/macrophage marker were incubated sequentially overnight at 4 °C. Sections 
were washed 3 times in PBS.  Appropriate secondary FITC-(green color) and Texas 
Red-(red color) conjugated antibodies were incubated with sections for 4 hours and 
washed off. Sections were finally mounted in an anti fading agent (Slowfade gold with 
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DAPI, Molecular Probes), and then the slides were observed and analyzed with the use 
of a fluorescence microscope (Zeiss Axioplan microscope with a 40X objective or a 
Nikon microscope with a 63X objective). 
3. Immunoblotting 
Coronary arterioles (4-6 vessels per sample) or heart tissues were separately 
homogenized and sonicated in lysis buffer (Cellytic™ MT Mammalian Tissue 
Lysis/Extraction Reagent, Sigma). Protein concentrations were assessed using a BCA™ 
Protein Assay Kit (Pierce), and equal amounts of protein were separated by SDS-PAGE 
and transferred to nitrocellulose or PVDF membranes (Pierce Biotechnology). IKKα 
(Santa Cruz), IKKβ (Abcam), p-IKKβ (Cell Signal), IκBα (Santa Cruz), p-IκBα (Santa 
Cruz), NFκB (Santa Cruz), TNFα (Santa Cruz), N-Tyr (Abcam), JNK, p-JNK (Abcam), 
IRS-1, and pIRS-1 (Millipore) antibodies were utilized to assess protein expression in 
mLeprdb, Leprdb, and Leprdb mice treated with anti-TNF (0.625 mg/ml/kg/day, i.p. for 3 
days), NAD(P)H oxidase inhibitor apocynin (100 mg/kg/day, i.p. for 3 days),34 NFκB 
antagonist MG132 (10 mg/kg/day, i.p. for 3 days), NaSal (6 mg/ml in drinking water), or 
SP600125 (10 mg/kg/day in 0.05 ml DMSO, i.p. for 7 days). MCP-1 (Abcam), N-Tyr 
(Abcam, an indicator for peroxynitrite-mediated tissue injury), VCAM, ICAM, and E-
selectin (Santa Cruz) protein expression were determined with  mLeprdb,  Leprdb, and 
Leprdb mice treated with anti-TNFα (0.625 mg/ml/kg/day, i.p. for 3 days). Signals were 
visualized by enhanced chemiluminescence (ECL, Amersham), and quantified by Fuji 
film imaging software. 
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4. Quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
RNA is first reverse transcribed into cDNA using a reverse transcriptase as 
described. The resulting cDNA is used as templates for subsequent PCR amplification 
using primers specific for one or more genes. RT-PCR can also be carried out as one-
step RT-PCR in which all reaction components are mixed in one tube prior to starting 
the reactions.  
Total RNA was extracted from heart tissue using Trizol reagent (Life 
Technologies Inc), and was processed directly to cDNA using the SuperScript™ III 
Reverse Transcriptase (Life Technologies Inc). The primers of IKKα and IKKβ were 
designed (Beacon software) and synthesized (Invitrogen).  cDNA was amplified using a 
qRT-PCR Kit with SYBR® Green (Life Technologies Inc). Data were calculated by 2-
∆∆CT method and presented as fold change of transcripts for IKKα and IKKβ gene in 
Leprdb mice normalized to β-actin, compared with mLeprdb mice (defined as 1.0 fold). 
∆∆CT=(CT-target-CT- β-actin) Leprdb - (CT-target-CT- β-actin) mLeprdb  
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CHAPTER III 
DATA ANALYSIS I 
 
Table 1. Serum parameters in mice with NaSal. 
 
Body weight and serum parameters were measured at 12-16 weeks for the different 
strains of mice (Table 1). Leprdb mice were treated with NaSal for 7-10 days and serum 
was collected from non-fasting mice in the morning. Non-fasting measurements were 
required since the Leprdb murine model was intolerant to a fasting protocol. Data 
represent mean ± SD, n=8. *p<0.05 vs mLeprdb,    #p<0.05 vs Leprdb.  
 
A. Roles of IKKα and IKKβ in Type 2 Diabetes 
To evaluate the roles of IKKα and IKKβ in diabetes, Leprdb mice were treated 
with anti-TNF, NAD(P)H oxidase inhibitor apocynin, and NFκB antagonist MG132. 
Protein expression of IKKα and IKKβ were increased in Leprdb mice (Figure 2). IKKβ 
expression was significantly attenuated in Leprdb mice treated with MG-132 or apocynin, 
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or in dbTNF-/dbTNF- mice vs. Leprdb mice. However, the alteration of IKKα expression 
was not observed in Leprdb mice treated with neutralizing antibody to TNFα, or in dbTNF-
/dbTNF- mice.  These findings suggest a link among IKKβ, NFκB, NAD(P)H oxidase and 
TNFα in coronary arterioles from mice with type 2 diabetes. 
 
 
 
Figure 2. Analysis of IKK subunit expression. (a) Anti-TNF attenuated IKKβ, not IKKα 
protein expression in Leprdb mice. (b) mRNA expression of  IKKα and  IKKβ are 
presented as relative (i.e., -fold) changes in Leprdb compared with control mice. Data are 
normalized to β-actin expression levels. Data represent mean±SD, n=4.  * p<0.05 vs. 
mLeprdb ; # p<0.05 vs. Leprdb.  
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B. Activation of IKKβ, NFκB and Degradation of IκBα-induced by TNFα 
Phosphorylation of IKKβ activates IκBα to decrease NFκB inhibitory action of IκBα. 
In Leprdb mice heart, protein expression of p-IKKβ was higher, but expression of p-
IKKβ was attenuated by anti-TNF, MG132, apocynin or in dbTNF-/dbTNF- mice  (Figure 
3). In Leprdb mice heart, protein expression of IκBα was lower (Figure 4a) vs. mLeprdb 
mice. However, protein expression of p-IκBα was higher in Leprdb vs. mLeprdb mice. 
Protein expression of p-IκBα was attenuated in dbTNF-/dbTNF- and Leprdb mice treated 
anti-TNF, apocynin or MG-132 vs. mLeprdb mice (Figure 4b). In Leprdb mice heart, 
protein expression of NFκB was higher, but apocynin, MG-132 or dbTNF-/dbTNF- mice 
presented a reduced protein expression of NFκB (Figure 4c).  
 
 
Figure 3. IKKβ activity. Protein expression of p-IKKβ was higher in Leprdb vs. mLeprdb. 
Data represent mean±SD, n=4. *p<0.05 vs. mLeprdb; #p<0.05 vs. Leprdb. 
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Figure 4. Analysis of IκBa and NFκB expression. Data represent mean±SD, n=4. 
*p<0.05 vs. mLeprdb; #p<0.05 vs. Leprdb. 
 
C. Role of Oxidative Stress in Type 2 Diabetes-induced Vascular Dysfunction 
Vasodilation to the endothelium-dependent vasodilator ACh was significantly 
impaired in Leprdb vs. mLeprdb mice (Figure 5a), but NFκB antagonist MG-132 partially 
restored endothelium-dependent coronary arteriolar dilation in Leprdb mice. The EPR 
result showed that O2˙¯  production was elevated and MG-132 decreased O2˙¯  production 
in Leprdb vs. mLeprdb mice (Figure 5b).  
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Figure 5. NFκB induces O2˙¯  production. (a) Leprdb mice impaired but MG132 treatment 
significantly restored ACh-induced endothelial-dependent vasodilation. (b) O2˙¯  
production from isolated coronary arterioles was higher in Leprdb mice vs. mLeprdb mice, 
and MG132 attenuated O2˙¯  production in Leprdb mice. Values were normalized to the 
mean value of mLeprdb, n=5.  *p<0.05 vs. mLeprdb; #p<0.05 vs. Leprdb. 
 
D. Effect of NaSal on Improvement of Insulin Sensitivity 
Blood glucose, body weight, abdominal girth, lipid levels and insulin levels were 
higher in Leprdb vs. mLeprdb mice. There were no significant differences in body weight, 
abdominal girth, lipid levels and insulin levels before and after treatment with NaSal in 
Leprdb mice (See Table 1). Lower values of glucose concentration and HOMA-insulin 
resistance were found in Leprdb mice treated with NaSal. The average body weight loss 
of Leprdb mice was 2.3 ± 2.5 mg after 7 days administration with 6 mg/ml of NaSal in 
drinking water. Insulin tolerance test (Figure 6) showed a significant difference in the 
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glucose clearance rate at 120 minutes after insulin administration in Leprdb mice treated 
with NaSal compared to Leprdb mice.  
 
     
Figure 6. Insulin tolerance test. Insulin was injected (0.75 U/kg, i.p.) and blood samples 
were taken for glucose determinations 0, 30, 60, and 120 minutes later. (a) Insulin 
tolerance test showed that the glucose clearance rate at 120 minutes after insulin 
administration in Leprdb mice treated with NaSal was significantly higher compared to 
Leprdb mice. The value was normalized to the basal glucose level.  (b) Actual glucose 
level. Data represent mean±SEM, n=6-8.  *p<0.05 vs. mLeprdb; #p<0.05 vs. Leprdb.  
 
E. Role of NaSal in Vascular Dysfunction in Type 2 Diabetes 
To establish the role of IKKβ in the signaling pathway, we studied whether the 
blockade of IKKβ improves endothelium-dependent vasodilation in Leprdb mice.  
     19 
 
 
Figure 7. NaSal improves arteriolar function. (a) ACh-induced vasodilation in isolated 
mice coronary arterioles was blunted in Leprdb vs. mLeprdb mice, and NaSal partially 
restored this dilation in Leprdb mice. (b) NaSal partially restored flow-induced 
vasodilation in Leprdb mice. (c) SNP-induced dilation in coronary arterioles was 
identical between mLeprdb and Leprdb mice. NaSal did not affect SNP-induced 
vasodilation in Leprdb mice. n=5; *p<0.05 vs. mLeprdb; #p<0.05 vs. Leprdb.  
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Functional results (Figure 7) showed that NaSal partially restored the ACh- and 
flow-induced endothelium-dependent vasodilation in Leprdb mice. SNP-induced 
vasodilation was equivalent in mLeprdb and Leprdb mice, indicating that function of 
smooth muscle was preserved. 
 
F. Insulin Resistance Enhanced Activity of JNK and IKKβ in Type 2 Diabetes 
Western blotting (Figure 8) showed that protein expression of TNFα, NFκB, 
phosphorylation of IKKβ and phosphorylation of JNK were greater in Leprdb mice heart, 
but NaSal attenuated the protein expression of TNFα, NFκB, phosphorylation of IKKβ 
and phosphorylation of JNK in Leprdb mice heart. Phosphorylation of insulin-receptor 
substrate-1 on serine site blocks insulin signaling transduction in diabetes. Protein 
expression of IRS-1 (Figure 9a) was significantly reduced in Leprdb, Leprdb treated with 
NaSal and Leprdb treated with JNK inhibitor SP600125 vs. mLeprdb mice. The ratio of 
pIRS-1 and IRS-1 was significantly higher in Leprdb, Leprdb treated with NaSal and 
Leprdb treated with JNK inhibitor SP600125 vs. mLeprdb mice. However, protein 
expression of phosphorylation of IRS-1 (pIRS-1, Ser307) was unaffected (Figure 9b) in 
Leprdb, Leprdb treated with NaSal and Leprdb treated with JNK inhibitor SP600125 vs 
mLeprdb. 
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Figure 8.  Effect of NaSal on IKKβ and JNK activity. Protein expression of p-IKKβ, p-
JNK, NFκB and JNK were greater in Leprdb mice vs. mLeprdb mice, but NaSal decreased 
protein expression of p-IKKβ, p-JNK, NFκB and JNK, without affecting protein 
expression of IKKβ and JNK. Data represent mean±SD, n=5. *p<0.05 vs. mLeprdb ; 
#p<0.05 vs. Leprdb. 
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Figure 9. Protein expression of IRS-1 ser307. (a) Total insulin receptor substrate-1 (IRS-
1) protein expression was decreased in Leprdb vs. mLeprdb mice. NaSal and SP600125 
treatment did not increase IRS-1 expression. (b) p-IRS-1 (Ser307) protein expression 
was elevated in Leprdb compared with mLeprdb control mice and both NaSal and 
SP600125 treatment appeared to reduce p-IRS-1 protein expression although there was 
no statistically  significant difference between groups. (c) Ratio of p-IRS-1 to total IRS-1 
was significantly higher in Leprdb vs. mLeprdb mice. NaSal and SP600125 treatment 
reduced p-IRS-1/IRS1. Data represent mean±SD, n=8. *P<0.05 vs. mLeprdb;  # P<0.05 
vs. Leprdb. 
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Figure 10. Putative TNFα/ NFκB and insulin signaling pathways. This schematic shows 
the correlative and causative relationship between inflammation and insulin resistance 
and depicts our proposed mechanism(s) by which NaSal sensitizes insulin signaling. 
TNFα triggers the activation of IKKβ  (rather than IKKα) to initiate processes leading to 
inflammation. NFκB is free to translocate and bind to DNA on the target genes when 
IκBα is phosphorylated by IKKβ, ubiquitinated and degraded by S26 proteasome. NFκB 
is involved in many aspects of the inflammatory response, e.g. induction of TNFα, 
MCP-1, and adhesion molecules. NFκB itself is induced by stimuli such as pro-
inflammatory cytokines. On the other hand, JNK and IKKβ induce IRS-1 serine 
phosphorylation to block insulin signaling in type 2 diabetes. 
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CHAPTER IV 
DATA ANALYSIS II 
 
Table 2. Serum parameters in mice with anti-MCP-1. 
 
Glucose concentration and cholesterol level are higher in Leprdb and Leprdb mice 
treated with anti-MCP-1(0.2 g/kg/day, 3 days) than in mLeprdb control mice (P<0.05, 
n=8). Abdominal girth was higher in Leprdb and Leprdb mice treated with anti-MCP-1 vs. 
mLeprdb on the day of surgery (n=8). * p<0.05 vs. mLeprdb ; # p<0.05 vs. Leprdb.  
 
A. TNFα and MCP-1 Amplification of Signaling in Coronary Arterioles in Type 2 
Diabetes 
 
We determined if TNFα and MCP-1 interact in their protein expressions. Protein 
expression of TNFα and MCP-1 from isolated coronary arterioles was analyzed in 
mLeprdb, Leprdb and Leprdb mice treated with anti-TNFα or anti-MCP-1. Western blot 
analysis (Figure 11) revealed that anti-TNFα markedly decreased MCP-1 expression and 
     25 
similarly anti-MCP-1 decreased TNFα expression, indicating there is an association 
between MCP-1 and TNFα signaling.  
 
           
Figure 11. Interaction between TNF and MCP-1. (a) Protein expression of TNFα from 
isolated coronary arterioles was higher in Leprdb vs. mLeprdb mice, but anti-MCP-1 
attenuated TNFα expression in Leprdb mice. (b) MCP-1 expression was elevated in 
Leprdb vs. mLeprdb mice, but anti-TNFα attenuated MCP-1 expression in Leprdb mice. 
Data represent mean±SD, n=4. * p<0.05 vs. mLeprdb ; # p<0.05 vs. Leprdb. 
 
B. Cellular Source of MCP-1 Expression in Type 2 Diabetes 
Immunostaining (Figure 12) showed that MCP-1 protein expression (red) was 
present in endothelial cells, but not in vascular smooth muscle cells. Lean control 
(mLeprdb) heart (A,B,C), Leprdb mice (D,E,F), Leprdb mice with anti-TNFα treatment 
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(G,H,I) and Leprdb mice with anti-MCP-1 treatment (J,K,L). The expression of MCP-1 
was decreased in Leprdb mice with anti-TNFα and anti-MCP-1 treatment. Negative 
control (M,N,O) shows an absence of staining in vessels with the secondary antibodies. 
Additionally, MCP-1 expression was higher in Leprdb than in mLeprdb mice, but anti-
TNFα or anti-MCP-1 decreased MCP-1 expression in Leprdb mice. Leprdb heart yielded 
a high percentage (70 %) of MCP-1 positive staining in the vessels, but a lower 
percentage of MCP-1 positive staining was presented in Leprdb mice treated with anti-
MCP-1 (30 %) or anti-TNFα (40 %) comparable to that in mLeprdb mice (15%). We 
quantified MCP-1 expression in vessels by counting the specific stained MCP-1 per 
section and normalized to mean value of mLeprdb mice (data not shown). Experiments 
were performed without the primary antibodies to test whether or not staining was 
related to the non specific binding of the secondary antibodies, which showed no 
staining in heart sections, indicating that the signals were due to specific binding of the 
primary antibody.  
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Figure 12. Co-localization of MCP-1 in microvessels. (A) Dual fluorescence combining 
MCP-1 and endothelial cells (von Willebrand factor [VWF] or vascular smooth muscle 
cells (α-actin, Figure 12b) or using specific antibodies followed by a fluorescent-labeled 
secondary antibody. (B) Dual fluorescence combining MCP-1 with markers for smooth 
muscle [α-actin]. Bar size is 50 µm. Original Magnification x 40. Data shown are 
representative of 4 separate experiments. * p<0.05 vs. mLeprdb ; # p<0.05 vs. Leprdb.  
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C. Role of MCP-1 in Type 2 Diabetes-Induced Vascular Dysfunction 
 Vasodilation to the endothelium-dependent vasodilator Ach was impaired in Leprdb 
mice compared to mLeprdb mice (Figure 13). Conversely, neutralizing antibody to MCP-
1 partially restored coronary arteriolar dilation-induced by Ach in Leprdb mice. To 
address whether over-expression of MCP-1 influences enhanced oxidative stress in 
Leprdb mice, we analyzed protein expression of N-Tyr (Figure 14b) to infer the 
concentration of peroxinitrite (ONOO¯ ), and measured O2˙¯  production (Figure 14a). 
Multiple bands revealed that protein expression of N-Tyr was higher in Leprdb mice vs 
mLeprdb mice, but neutralization of MCP-1 attenuated protein expression of N-Tyr in 
Leprdb mice. The EPR result showed that O2˙¯  production was elevated and 
neutralization of MCP-1 decreased O2˙¯  production in Leprdb mice. 
 
 
 
 
 
 
 
 
Figure 13. Role of MCP-1 on endothelial function. Neutralizing antibodies to MCP-1 
restored coronary arteriolar dilation to Ach in Leprdb mice, but did not affect the 
vasodilation to Ach in mLeprdb mice.  * p<0.05 vs. mLeprdb ; # p<0.05 vs. Leprdb. 
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Figure 14. Effect of neutralizing MCP-1 in Leprdb on oxidative stress. (a) Superoxide 
anion (O2˙¯ ) production (n=6) is higher in Leprdb mice than in lean controls (mLeprdb). 
Anti-MCP-1 reduced the production of superoxide in Leprdb mice. (b) Protein expression 
of nitrotyrosine from coronary arterioles was determined. The results are shown for 
nitrotyrosine bands migrating at 52- and 45-kDa. Both 52- and 45-kDa bands of 
nitrotyrosine are higher in Leprdb mice than in mLeprdb mice and Leprdb mice treated 
with anti-MCP-1. Data represent mean±SD, n=4. * p<0.05 vs. mLeprdb ; # p<0.05 vs. 
Leprdb. 
 
D. TNFα and MCP-1-induced Macrophage Recruitment and Activation 
We further investigated the biological function of MCP-1; responsible for 
chemoattraction of circulating monocyte-derived macrophages. Immunostaining analysis 
(Figure 13), revealed co-expression of the monocyte/macrophage marker CD68 and 
MCP-1 expression was increased about 3 fold in Leprdb vs. mLeprdb mice. Anti-TNFα or  
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Figure 15. Co-localization of MCP-1 in macrophages. Heart sections from lean control 
(mLeprdb) (A,B,C), Leprdb (D,E,F), and Leprdb mice with anti-TNFα treatment (G,H,I) 
and Leprdb mice with anti-MCP-1 treatment (J,K,L). Macrophage infiltration is 
significantly increased in Leprdb mice compared to mLeprdb mice and decreased after 
anti-TNFα and anti-MCP-1 treatment to Leprdb mice. Negative control (M,N,O) shows 
an absence of staining in vessels with only the secondary antibodies. Original 
magnification 16X. Data shown are representative of 4 separate experiments. * p<0.05 
vs. mLeprdb ; # p<0.05 vs. Leprdb. 
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anti-MCP-1 treatment reduced infiltration of macrophages by 2 and 1.5 fold, 
respectively, in Leprdb mice, which suggests that coronary arteriolar dysfunction might 
be associated with macrophage influx. We quantified macrophage infiltration by 
counting the specifically stained macrophages per equal unit area and normalized to the 
mean value of mLeprdb mice.  
 
E. TNFα and MCP-1-induced Adhesion Molecules and Macrophage Infiltration 
Dual fluorescence combining VCAM with markers for endothelial cells (von 
Willebrand factor [VWF]) (A~F), vascular smooth muscle cells [α-actin] (G~O) or 
macrophages [CD68] (P~R) using specific antibodies followed by a fluorescent labeled 
secondary antibody. Arrows show co-localization of VCAM in endothelial cells and 
specific stain of VCAM inside vascular smooth muscle cells or co-localization of 
VCAM in infiltrated macrophage in diabetic mice (Leprdb). No primary antibody control 
(S~U) shows an absence of staining in vessels with secondary antibodies. Figure 16a 
shows increased protein expression of VCAM-1 (red) in the heart of Leprdb vs mLeprdb 
mice, which is consistent with the elevated protein expression detected by western blot 
analysis (Figure 16 b-d). We analyzed protein expression of adhesion molecules; VCAM, 
ICAM, and E-selectin to test whether they are correlated with increased expression of 
cytokines (e.g., TNFα and MCP-1) in Leprdb mice. The concentration of adhesion 
molecules was elevated in Leprdb mice vs. mLeprdb mice but attenuated after 
administration with anti-TNFα.   
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Figure 16. Analysis of adhesion molecule expression. (a) Bar size is 50µm. Original 
magnification: 63X. Data shown are representative of 4 separate experiments. (b) Protein 
expression of VCAM, (c) ICAM, and (d) E-selectin from coronary arterioles was 
determined. Data represent mean±SD, n=4. * p<0.05 vs. mLeprdb ; # p<0.05 vs. Leprdb. 
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CHAPTER V 
SUMMARY AND CONCLUSION 
 
First, our results in feed-forward Signaling of TNFα and NFκB via IKKβ 
Pathway suggest that the interaction of NFκB and TNFα signaling induces activation of 
IKKβ and amplifies oxidative stress, leading to endothelial dysfunction in coronary 
arterioles of Leprdb mice, a model for obesity and type 2 diabetes. Importantly, our 
findings also support the concept that feed-forward signaling of TNFα and NFκB via the 
IKKβ pathway induces insulin resistance and coronary arteriolar dysfunction in type 2 
diabetes based on the following observations: NFκB antagonist MG-132, or IKKβ 
inhibitor NaSal, restored endothelium-dependent coronary arteriolar dilation in Leprdb 
mice, but the responses in mLeprdb mice were unaffected. Protein expression of IKKα 
and IKKβ were higher in Leprdb than in mLeprdb mice; the expression of IKKβ, but not 
the expression of IKKα, were attenuated by MG-132, NAD(P)H oxidase inhibitor 
apocynin or in dbTNF-/dbTNF- mice. Insulin resistance was increased in Leprdb mice and 
NaSal improved insulin sensitivity. Protein expression of TNFα, NFκB, phosphorylation 
of IKKβ and JNK were greater in Leprdb mice, but NaSal attenuated protein expression 
of TNFα, NFκB, phosphorylation of IKKβ and JNK in Leprdb mice. The pIRS-1/IRS-1 
ratio was elevated in Leprdb compared with mLeprdb mice. Both NaSal and the JNK 
inhibitor SP600125 reduced the pIRS-1/IRS-1 ratio in Leprdb mice. MG-132 (Figure 5b) 
or anti-TNFα5 reduced O2˙¯  production in Leprdb mice. NFκB induces TNFα signaling 
to accentuate oxidative stress and endothelial dysfunction via an IKKβ dependent 
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mechanism, which may be associated with inflammatory and insulin signaling pathways 
in type 2 diabetes. Our findings are consistent with NFκB involvement, by interacting 
with TNFα, thereby inducing IKKβ and NAD(P)H oxidase, in endothelial dysfunction 
in type 2 diabetes. The present molecular results further support our previous 
physiological observations that increases in TNFα expression induce activation of 
NAD(P)H oxidase and production of ROS, leading to endothelial dysfunction in type 2 
diabetes.5 
 
A. Roles of Interaction of TNFα and NFκB Signaling on Impaired Coronary Arteriolar 
 Responses in Type 2 Diabetes  
 
The inducible transcription factor NFκB regulates the expression of genes 
encoding oxidants, cytokines, chemokines and adhesion molecules, which are associated 
with inflammation and activated by gene products of NFκB, e.g., a feed-forward 
interaction.5,35-37 These pro-inflammatory agents play a detrimental role in vascular 
pathology and TNFα initiates signaling cascades that converge on the IKK complex via 
the NFκB signaling pathway. We previously found that TNFα signaling leads to 
oxidative stress via NAD(P)H oxidase activation and perhaps via activating NFκB, 
which in turn may lead to further increases in TNFα expression leading to endothelial 
dysfunction in type 2 diabetic mice.5 TNFα is an inducer of IKKβ and IκBα in the 
classical NFκB pathway. Thus, TNFα initiates signaling cascades predominantly acting 
through IKKβ.38,39 In this study, we examined whether feed-forward interaction between 
TNFα and NFκB, via the IKKβ pathway, amplify one another toward the evolution of 
     35 
vascular disease and insulin resistance in type 2 diabetes. Our western blotting results 
showed that protein expression of IKKα and IKKβ were higher in Leprdb than in mLeprdb 
mice. MG-132, NAD(P)H oxidase inhibitor, apocynin, or dbTNF-/dbTNF- mice attenuated 
the expression of IKKβ, but not the expression of IKKα. This points to a linkage among 
IKKβ, NFκB, NAD(P)H oxidase and TNFα in contributing to type 2 diabetes. 
Biological activity of NFκB is controlled mainly by IκBα protein, which binds to 
NFκB in the cytoplasm and inhibits DNA binding activity. IκB blocks a nuclear 
translocation signal to inactivate NFκB in the cytoplasm and removes NFκB bound to 
promoters in the nucleus.6 MG-132 has been shown to inhibit the degradation of IκBα. 
Our results showed that protein expression of IκBα was lower. However, protein 
expression of p-IκBα was higher in Leprdb mice compared to mLeprdb mice. In dbTNF-
/dbTNF- and Leprdb mice treated with anti-TNF, apocynin or MG-132, protein expression 
of p-IκBα was attenuated. In Leprdb mice, protein expression of NFκB was higher, but 
apocynin, MG-132 or dbTNF-/dbTNF- mice reduced protein expression of NFκB, 
indicating that TNFα, NAD(P)H oxidase and IκBα degradation may increase the activity 
of NFκB. Our functional results showed that ACh-induced vasodilation was impaired in 
Leprdb mice vs. mLeprdb mice, but NFκB antagonist MG-132 partially restored ACh-
induced coronary arteriolar dilation in Leprdb mice. The EPR results showed that O2˙¯  
production was elevated and MG-132 decreased O2˙¯  production in Leprdb mice, which 
indicates that blocking NFκB transcriptional action markedly attenuated O2˙¯  production 
in isolated coronary arterioles in Leprdb mice. This supports the concept that diabetes 
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increases NAD(P)H oxidase activity through the interaction of TNFα/NFκB signaling, 
which in turn accentuates oxidative stress and induces endothelial dysfunction via an 
IKKβ activation. Our results are consistent with the concept that IKKβ is a putative 
activator of NFκB, which is thought to alter subsequent gene expression in this 
pathway.35-37  
 
B. The Role of IKKβ in Vascular Dysfunction in Type 2 Diabetes 
 NaSal is an IKKβ inhibitor that interrupts the cascade of molecular events 
leading to inflammation. Yuan et al. showed that reduced signaling through the IKKβ 
pathway inhibition by NaSal in obese mice is accompanied by improved insulin 
sensitivity.9 Recent studies noted that NFκB blockade (by inhibiting IKKβ activity) 
decreased myocardial injury and preserved cardiac function following ischemia-
reperfusion,10 which supports the concept that the inflammatory response participates in 
the development of heart failure.39 Our results showed that phosphorylation of IKKβ 
increases in diabetes, but blockade of NFκB and NAD(P)H oxidase and dbTNF-/dbTNF- 
mice attenuated phosphorylation of IKKβ, suggesting that 1) IKKβ activity increases in 
diabetes; and 2) phosphorylation of IKKβ increases in diabetic mice by activation of 
NAD(P)H oxidase and TNFα. This indicates that TNFα-induced phosphorylation of 
IKKβ is followed by phosphorylation of IκBα to release NFκB into the nucleus. 
The pathogenesis of endothelial dysfunction in diabetes is initially related to a 
decrease in NO synthesis or inactivation of NO due to increased endothelial production 
of ROS.41 An underlying mechanism proposed for TNFα induced endothelial 
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dysfunction is that TNFα signaling leads to oxidative stress via NAD(P)H activation, 
which in turn may lead to reduced NO bioactivity.5,34 We identified a link between 
vascular dysfunction and insulin resistance in that treatment with NaSal in coronary 
microcirculation resulted in an improvement of endothelial dysfunction in diabetic 
Leprdb mice. The NO donor SNP induced an identical vasodilation in Leprdb and 
mLeprdb mice, but ACh-induced vasodilation was impaired in isolated coronary 
arterioles in diabetic Leprdb mice, which indicates that endothelium-dependent 
vasodilation is impaired in diabetes. Most importantly, NFκB antagonist MG132 or 
IKKβ inhibitor NaSal partially restored endothelium-dependent coronary arteriolar 
dilation in type 2 diabetes. These results further support our hypothesis that TNFα and 
NFκB signaling via an IKKβ dependent mechanism plays a key role in endothelial 
dysfunction in diabetes.  
Blood glucose, body weight, abdominal girth, lipid level and insulin level were 
higher in Leprdb vs. mLeprdb mice, and there were no significant differences in body 
weight, abdominal girth, lipid level and insulin level before and after treatment with 
NaSal. However, lower values of glucose concentration and HOMA-insulin resistance 
found in Leprdb mice treated with NaSal indicate that NaSal improved insulin sensitivity 
in Leprdb mice (Table 1). Insulin tolerance test in Figure 6 shows that there was a 
significant difference in the glucose clearance rate at 120 minutes after insulin 
administration in Leprdb mice treated with NaSal compared to Leprdb mice. Our results 
indicate that hyperglycemia and insulin resistance in Leprdb mice were amended by a 
short-term treatment with NaSal via a downregulation of IKKβ and NFκB signaling. 
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Increased phosphorylation of IKKβ may also contribute to the development or 
progression of the vascular disease and hyperglycemia in type 2 diabetes. 
 
C. Link between Inflammation-induced Insulin Resistance and Vascular Dysfunction 
Coronary artery disease causes acute myocardial infarction, which is associated 
with significant morbidity and mortality in patients with diabetes. Diabetes is associated 
with alterations in cardiac energy metabolism, characterized by reduced glucose 
utilization, and increased utilization of fatty acids as a metabolic substrate.42 The data 
show that insulin may also modulate cardiac myocyte metabolism through paracrine 
mechanisms by activating insulin receptors in the heart,11 thereby decreasing myocardial 
infarct size and increasing cardiac contractility.12,13  Human type 2 diabetes is currently 
characterized by defects in both insulin action and insulin secretion, which lack the focus 
needed to identify a single molecular abnormality underlying these features, if indeed 
one exists. Insulin-receptor substrates (IRS proteins) may be involved in type 2 
diabetes43 and tyrosine phosphorylation activates insulin IRS-1, which further leads to 
the translocation of glucose transporters (GLUT4) to the cell surface.44 Impaired 
transcription of the major cardiac glucose transporter GLUT4 is seen within 4 days after 
the induction of diabetes.45 IKKβ may affect glucose metabolism by altering NFκB 
transcriptional action to express GLUT4.46 JNK is a main regulatory molecule that 
contributes to coronary arteriolar dysfunction and insulin resistance.14,47 IRS-1 tyrosine 
phosphorylation by Akt induces insulin signal transduction.15 Serine phoshphorylation 
by JNK can downregulate or inactivate IRS-1. The impaired activation of Akt and 
enhanced activation of JNK by TNFα is correlated with insulin resistance.47 Sholeson et 
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al. reported that inflammation-induced insulin resistance and noted that two signaling 
pathways are linked to the proinflammatory effects of obesity and type 2 diabetes. Both 
NFκB/IKKβ and JNK pathways are activated by TNFα in liver or adipose tissue. 
Genetic disruption of NFκB and JNK signaling pathways has been shown to improve 
insulin resistance.1 Consistent with the findings described above, inhibition of IKKβ or 
JNK activity by NaSal significantly reduced blood glucose level and augmented insulin 
signaling in cardiac tissue. Our results showed that protein expression of TNFα and 
NFκB were higher in diabetic mice, but NaSal attenuated protein expression of TNFα 
and NFκB. Specifically, NaSal attenuated phosphorylation of IKKβ and JNK without 
altering protein expression of IKKβ and JNK. This suggests that NaSal interrupts 
phosphorylation of IKKβ, which may in turn decrease phosphorylation of JNK. TNFα 
activates the IKKβ and JNK signaling pathway and, conversely, the expression of the 
TNFα gene is regulated by NFκB through activation of IKKβ. IKKβ and c-JNK 
phosphorylate specific serine sites (e.g., Ser307) on the insulin receptor and /or insulin 
receptor substrate-1 (IRS-1). Serine phosphorylation of IRS-1 blocks insulin-stimulated 
tyrosine phosphorylation at IRS-1 and reduces downstream insulin signaling, resulting in 
reduced GLUT4 translocation and insulin resistance.48,49 
To further elucidate the signaling pathway involved in the recovery of insulin 
action in cardiac tissue, we tested whether insulin receptor substrate-1 serine 
phosphorylation is attenuated by SP600125 and NaSal. Phosphorylated IRS-1 (pIRS-1) 
protein expression was elevated in Leprdb compared with mLeprdb mice; both NaSal and 
JNK inhibitor SP600125 reduced pIRS-1 protein expression in Leprdb mice. Our results 
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indicate that TNFα, phosphorylation of JNK and IKKβ, and NFκB contribute to insulin 
resistance and vascular dysfunction probably via activation of IKKβ in type 2 diabetes. 
Interestingly, NaSal and JNK inhibitor SP600125 sensitize insulin signaling by 
preventing serine phosphorylation on IRS-1 from IKKβ and JNK. This indicates NaSal 
inhibits phosphorylation of IKKβ and JNK in insulin resistant diabetic murine hearts. 
The pIRS-1/IRS-1 ratio was elevated in Leprdb compared with mLeprdb mice; both NaSal 
and JNK inhibitor SP600125 reduced the pIRS-1/IRS-1 ratio in Leprdb mice. The 
postulated mechanism is that activation of IKKβ may directly stimulate JNK activation 
or cause an increase in TNFα expression. Consequently, this activation could aggravate 
insulin resistance by further limiting insulin signaling.  
In summary, our results demonstrated that TNFα was correlated with IKKβ, but 
not IKKα, to induce NFκB activation. Inhibition of IKKβ restored ACh-induced 
endothelium-dependent vasodilation in coronary arterioles in diabetes. Diabetic mice 
treated with NaSal showed a decrease in glucose level and a reversal of insulin 
resistance. Both IKKβ and JNK activation were increased in Leprdb mice and NaSal 
attenuated their activation without altering their expression levels. Overall, our 
molecular and functional results show that IKKβ is a crucial component of the 
biochemical pathway responsible for vascular dysfunction, inflammation, and insulin 
resistance in type 2 diabetic murine hearts. As noted above, diabetic mice treated with 
MG132 or NaSal showed partially restored ACh-induced vascular dysfunction. 
Blockade of IKKβ activity not only preserved coronary arteriolar vasodilation, but also 
prevented insulin resistance in type 2 diabetic mice. Although the current study 
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confirmed that NaSal amended whole body insulin sensitivity and demonstrated that 
IKKβ and NFκB signaling is associated with insulin resistance and inflammation in 
diabetic murine hearts, such a proposal needs to further validate how direct insulin 
signaling to coronary arterioles affects vessel function. Nevertheless, anti-diabetic 
effects of NaSal in vivo were observed in our study. Understanding these mechanisms 
regulating heart disease processes will provide new therapies to resolve these problems.  
Second, our results in role of MCP-1 in TNFα-induced endothelial dysfunction 
suggest that MCP-1 interacts with TNFα to amplify adhesion molecules and oxidative 
stress, thereby contributing to vascular dysfunction in coronary microcirculation in type 
2 diabetes. Our molecular evidence indicated that the expression of TNFα and MCP-1 
was significantly increased in Leprdb mice; but, anti-MCP-1 decreased TNFα protein 
expression and anti-TNFα attenuated MCP-1 expression. Antibody neutralization of 
MCP-1 prevented coronary endothelial dysfunction and reduced ONOO¯  and O2˙¯  
generation and formation of N-Tyr in Leprdb mice. Administration of anti-TNFα or anti-
MCP-1 to Leprdb mice resulted in attenuation in cardiac macrophage accumulation 
comparable to that in the control, suggesting that an interaction of MCP-1 and TNFα 
may accentuate the process of macrophage accumulation. Most importantly, blockade of 
TNFα or MCP-1 attenuated the expression of adhesion molecules (e.g., VCAM, ICAM, 
and E-selectin) in isolated coronary vessels in diabetes. We conclude that interactions of 
TNFα and MCP-1 signaling contribute to oxidative stress by increasing inflammatory 
cell accumulation and induce endothelial dysfunction in coronary arterioles in diabetic 
Leprdb mice. 
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D. Roles of TNFα and MCP-1 in Type 2 Diabetes 
 The important manifestation of diabetes-induced microvascular injury in the 
heart is a diminution in coronary blood flow. This is emphasized by clinical data 
showing ~25% of patients with acute myocardial infarction do not have adequate 
restoration of myocardial tissue perfusion in the infarct region, despite coronary artery 
recanalization.39 We previously found that increases in TNFα expression induces 
activation of NAD(P)H oxidase and production of ROS, leading to endothelial 
dysfunction in type 2 diabetes.5 The endothelium-derived NO is an important 
endogenous vasodilator that regulates microvascular tone.50 Consistent with our previous 
studies, our present study shows that neutralization of MCP-1 decreased TNFα protein 
expression and prevented coronary endothelial dysfunction in Leprdb mice. Our western 
blot results indicated that the expression of TNFα and MCP-1 were significantly 
increased in Leprdb mice; but, anti-MCP-1 decreased TNFα protein expression and anti-
TNFα attenuated MCP-1 expression. The evidence from our immunostaining in Leprdb 
mice showed that endothelial cells expressed MCP-1 (over 4.6-fold in microvessels), but 
Leprdb mice with anti-TNFα had attenuated MCP-1 expression (over 2.6-fold) in 
endothelial cells.  
MCP-1 is an important mediator in response to acute tissue injury that plays a 
putative role in host defense.27 Recent evidence suggests that MCP-1 also plays a role in 
the evolution of vascular disease through inducing adhesion molecule expression on/in 
endothelium and recruiting monocytes/macrophages at the inflammatory site.22-24 Our 
results in Table 2 show that anti-MCP-1 did not decrease insulin levels, but slightly 
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affected lipid metabolism by decreasing circulating cholesterol levels. The results 
suggest that MCP-1 plays a role in upregulating cholesterol level in blood. Despite the 
similarities in glucose, body weight, cholesterol level, insulin level and abdominal girth 
in diabetic animals, endothelial function was better in Leprdb mice treated with anti-
MCP-1. This suggests that MCP-1 signaling plays a pivotal role in attenuating TNFα 
protein expression, and TNFα is the key cytokine that induces endothelial dysfunction in 
type 2 diabetes.5 
 
E. The Role of MCP-1 in ROS Production in Coronary Arterioles in Type 2 Diabetes 
The link between diabetes and inflammation leading to vascular disease is associated 
with enhanced oxidative stress.5 Nitration of proteins is caused by peroxynitrite, a ROS 
formed by the reaction of nitric oxide (NO) with O2˙¯ ,51 which further consumes NO and 
increases oxidative stress. Numerous studies have noted that nitration of tyrosine occurs 
at high levels of peroxynitrite (ONOO¯ ) during the pathogenesis of human 
atherosclerosis (Figure 17).40,52  
 
 
Figure 17.  Potential pathway of tyrosine nitration oxidation.  
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In particular, decrease in expression of constitutive nitric oxide synthase (NOS) 
and inactivation of NO has been implicated in the endothelial dysfunction seen in type 2 
diabetes.40 Previous work detailed the role of TNFα, NFκB, and ROS in inflamed heart 
and vessels and suggested that they trigger NFκB activation to induce TNFα protein 
expression.5,53 The interaction between activated macrophages and endothelial cells 
produces an oxidative stress that affects the activation state of transcription factor 
NFκB.24 To test if MCP-1 enhances macrophage infiltration and induces ROS, 
macrophages derived from circulating monocytes were characterized by CD68 staining, 
which specifically labels macrophages and monocytes. Our immunostaining results 
showed that Leprdb mice expressed MCP-1 in macrophage (over 3-fold in heart sections), 
but anti-TNFα attenuated MCP-1 expression (2-fold in heart sections), which suggest 
that TNFα up-regulates MCP-1 expression in macrophages. Antibody neutralization of 
MCP-1 reduced ONOO¯  and O2˙¯  generation and formation of N-Tyr in Leprdb mice. 
This result suggests that TNFα initiates the interaction of macrophages and endothelial 
cells via upregulation of MCP-1 signaling, which results in macrophage infiltration and 
production of ROS. Based on the evidence that MCP-1 contains a kB site upstream from 
its promoters,24,54 NFκB may regulate both TNFα and MCP-1 gene expression in 
endothelial cells, thereby possibly inducing macrophage infiltration leading to vascular 
disease. 
One of the major events of endothelial dysfunction is vascular inflammation, 
which is associated with impaired vascular control. It appears that MCP-1 residing in the 
endothelium contributes to the regulation of vasodilation under diabetic conditions 
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because anti-MCP-1 significantly enhanced endothelium-dependent coronary arteriolar 
dilations and decreased O2˙¯  production in isolated blood vessels from diabetic mice. 
Our results support an endogenous role of vascular MCP-1 in regulating NO-mediated 
dilation of coronary microvessels in type 2 diabetes. Consistently, our molecular results 
showed that anti-MCP-1 decreased TNFα protein expression; anti-TNFα attenuated 
MCP-1 expression; and antibody neutralization of MCP-1 reduced ONOO¯  and O2˙¯  
generation and formation of N-Tyr in Leprdb mice. Of particular importance to this study 
is that MCP-1 and TNFα signaling plays a pivotal role in endothelial dysfunction, 
consistent with what might be expected in an inflammatory disease in coronary arterioles. 
 
F. Enhancement of Adhesion Molecules by MCP-1 and TNFα in Endothelial Cells  
in Diabetes 
 
Endothelial cells exert broad functions to maintain vessel homeostasis. The 
modification of the pattern of gene expression in the endothelial cells is a critical step 
during the progression of vascular disease. In endothelial cells, NFκB regulates the 
inducible expression of genes encoding chemokines and adhesion molecules.55 In our 
studies, the inflammatory cytokine TNFα has been explored as a factor in initiation or 
progression of vascular disease.5,28 Inflammatory mediators, MCP-1 and adhesion 
molecules, have also been implicated in the inflammatory processes related to TNFα in 
the development of vascular disease in type 2 diabetes.55 Elevated adhesion molecules in 
the vessels have been thought to be significantly associated with an increase in the risk 
of coronary arterial disease.16 E-selectin is important in monocyte arrest or the transition 
from slow rolling to firm adhesion. VCAM and ICAM are critical for firm attachment of 
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monocyte in the recruitment cascade.17 Immunostaining data showed that macrophages 
and endothelial cells express adhesion molecules and western blot analysis revealed that 
TNFα and MCP-1 increased expression of adhesion molecules (e.g., VCAM, ICAM, 
and E-electin), which suggest that elevated expression of adhesion molecules is the 
result of the release of cytokines, TNFα and MCP-1, from endothelial cells and 
macrophages in Leprdb mice. The actions of adhesion molecules are favored in small 
vessels (~ 50µm) compared to that seen in the large coronary arteries under normal 
conditions because of the lower flow and shear stress in diabetes.  
Monocyte-derived macrophages are mainly inflammatory cells. Macrophages 
contribute to the oxidation of LDL and oxidized LDL acts on mature macrophages to 
form macrophage foam cells.21,56 Initial low expression of adhesion molecules results in 
low affinity to ligands, and a signal from MCP-1 is essential to mobilize adhesion 
molecules for firm adhesion.22 Inflammatory mediators such as MCP-1 and adhesion 
molecules have been implicated in the inflammatory processes related to TNFα in the 
development of vascular disease in type 2 diabetes. Co-localization of MCP-1 and 
VCAM-1 with macrophages was observed in the myocardium, suggesting that MCP-1 
and cell adhesion molecules play a role in monocyte transmigration into the heart. 
ICAM-1 and E-selectin also co-exist in endothelial cells and macrophages (data not 
shown).  
Taken together, MCP-1 may play a critical role in inflammation-induced 
endothelial dysfunction in coronary arterioles in diabetes by increasing adhesion 
molecule expression in endothelial cells, thereby inducing macrophage infiltration at the 
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inflammatory site (Figure 18) without influencing the development of obesity or insulin 
resistance.  
 In this study, we found that beyond monocyte recruitment, MCP-1 is critical in 
TNFα-induced endothelial dysfunction in type 2 diabetes. The postulated mechanism is 
that MCP-1-induced the production of O2˙¯  and ONOO¯  in vascular endothelial cells, 
which then attenuated NO bioavailability and reduced NO mediated vasodilation in the 
coronary microcirculation in type 2 diabetes. Furthermore, inflammatory cell infiltration 
was enhanced via overexpression of TNFα and MCP-1-induced upregulation of cell 
adhesion molecules in coronary arterioles in type 2 diabetes. Our findings demonstrate 
that the endothelial dysfunction occurring in type 2 diabetes is the result of the effects of 
the inflammatory cytokine TNFα and TNFα−related signaling, including the expression 
of MCP-1, which also exacerbates the oxidative stress. 
 
     48 
 
Figure 18. Interactions among TNF, MCP-1 and adhesion molecules in endothelium. We 
illustrate a new aspect of the regulation of TNF-dependent signal transduction. Serine 
site phosphorylation by Akt is blocked and JNK phosphorylate at tyrosine site of insulin 
receptor substrate, leading to insulin resistance in type 2 diabetes. Interaction of TNF 
and MCP-1 induces expression of adhesion molecules, leading to increase of 
macrophage infiltration and oxidative stress, which further exacerbate vascular 
dysfunction. 
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